| Literature DB >> 29740217 |
Tao Gu1,2, Lei Lin3, Yun Jiang4, Juan Chen1, Ryan Cn D'Arcy2,5,6, Min Chen1, Xiaowei Song2,5,6.
Abstract
BACKGROUND: Acupuncture has been proven to be effective as an alternative therapy in treating migraine, but the pathophysiological mechanisms of the treatment remain unclear. This study investigated possible neurochemical responses to acupuncture treatment. PATIENTS AND METHODS: Proton magnetic resonance spectroscopy imaging was used to investigate biochemical levels pre- and post-acupuncture treatment. Participants (N=45) included subjects diagnosed with: 1) migraine without aura; 2) cervicogenic headache; and 3) healthy controls. Participants in the two patient groups received verum acupuncture using acupoints that target migraine without aura but not cervicogenic headache, while the healthy controls received a sham treatment. All participants had magnetic resonance spectroscopy scans before and after the acupuncture therapy. Levels of brain metabolites were examined in relation to clinical headache assessment scores.Entities:
Keywords: acupuncture; brain; magnetic resonance spectroscopy imaging; metabolites; migraine; pain transmission pathways
Year: 2018 PMID: 29740217 PMCID: PMC5931197 DOI: 10.2147/JPR.S162696
Source DB: PubMed Journal: J Pain Res ISSN: 1178-7090 Impact factor: 3.133
Experimental design
| Experiment design | Group | Migraine without aura | Cervicogenic headache | Healthy control |
|---|---|---|---|---|
| Sample size (female/male) | 10/5 | 10/5 | 10/5 | |
| Clinical assessment (week 1–4) | Headache intensity | On visual analog scores (0: no pain to 10: worst pain) | ||
| Headache frequency | The number of headaches separated by 48+ hours of pain-free intervals within the past 4 weeks | |||
| Duration of headache | The time in hours from the beginning till the end of a headache episode | |||
| MRS test at the end of week 4 | Sequence | 2D-multiple voxel PRESS | ||
| Location | Left thalamus, right thalamus, anterior cingulate cortex and posterior part of paracentral gyrus | |||
| Metabolite ratio | NAA/Cr, Cho/Cr, Cho/NAA | |||
| Intervention therapy (week 5) | Frequency | 1 time/day for 5 days | ||
| Method | Acupuncture | |||
| Acupoints | Verum | |||
| MRS test at the end of week 5 | Sequence | 2D-multiple voxel PRESS | ||
| Location | Left thalamus, right thalamus, anterior cingulate cortex and posterior part of paracentral gyrus | |||
| Metabolite ratio | NAA/Cr, Cho/Cr, Cho/NAA | |||
| Clinical assessment (week 6–9) | Headache intensity | On visual analog scores (0: no pain to 10: worst pain) | ||
| Headache frequency | The number of headaches separated by 48+ hours of pain-free intervals within the past 4 weeks | |||
| Duration of headache | The time in hours from the beginning till the end of a headache episode | |||
Note:
Baihui (DU20), bilateral Fengchi (GB20) and Xingjian (LR2) for patients of both groups.
10 mm straight medial from the Baihui (DU20), bilateral Fengchi (GB20) and Xingjian (LR2) for healthy controls.
Abbreviations: MRS, magnetic resonance spectroscopy; PRESS, single-voxel point-resolved spectroscopy; NAA, N-acetylaspartate; Cr, creatine; Cho, choline-containing compounds.
Figure 1Locations of the targeted VOI superimposed on T2-weighted imaging (left panels) and the corresponding sample MRS spectra (right panels).
Note: From top to bottom: left thalamus (TH-left); right thalamus (TH-right); anterior cingulate gyrus (ACC); posterior part of paracentral gyrus (PPG). Red grids show B0 shimming; green-lined rectangles show the VOIs; yellow squares show the voxels from which the spectra were retrieved and averaged for analysis.
Abbreviations: VOIs, voxels of interest; MRS, magnetic resonance spectroscopy; NAA: N-acetylaspartate; Cr: creatine; Cho: choline-containing compounds.
Characteristics of the sample
| Group | Migraine without aura | Cervicogenic headache | Healthy control |
|---|---|---|---|
| N (female/male) | 10/5 | 10/5 | 10/4 |
| Age (years) | 34.8±10.6 | 43.3±12.1 | 22.4±1.1 |
| Headache history (years) | 16.3±9.8 | 4.3±3.0 | 0 |
| Headache intensity (VAS | 7.0±1.5 | 4.7±1.0 | 0 |
| Headache frequency | 4.0±3.4 | 3.9±3.5 | NA |
| Duration of headache | 12.1±10.5 | 3.5±3.0 | NA |
| Headache intensity (VAS | 6.3±1.3 | 4.5±0.8 | 0 |
| Headache frequency | 3.6±2.7 | 3.9±3.4 | NA |
| Duration of headache | 10.9±10.1 | 3.3±2.8 | NA |
Notes: Data are presented as mean±standard deviation; value ranges are given in the square brackets.
VAS: visual analog scores (0=no pain to 10=worst pain ever)
Defined as the number of headaches separated by pain-free intervals of at least 48 hours within the past 4 weeks.
Defined as the time in hours from the beginning until the end of the headache episode.
Significant difference between baseline and follow-up.
Abbreviations: VAS, visual analog score; NA, not applicable.
Levels of metabolites comparing different subject groups at pre- and post-intervention conditions
| Brain region | Metabolite ratio | Time | Migraine without aura (n=15) | Cervicogenic headache (n=15) | Healthy control (n=14) |
|---|---|---|---|---|---|
| Left thalamus | NAA/Cr | 1 | 1.91±0.22 | 1.94±0.27 | 2.36±0.36 |
| 2 | 2.11±0.35 | 1.86±0.20 | 2.35±0.41 | ||
| Statistics T(P) | 3.43 (0.006) | –1.49 (0.160) | –0.11 (0.913) | ||
| Cho/Cr | 1 | 1.00±0.08 | 1.08±0.09 | 0.95±0.16 | |
| 2 | 1.05±0.13 | 1.01±0.06 | 1.04±0.13 | ||
| Statistics T(P) | 1.63 (0.132) | –2.11 (0.068) | 1.69 (0.116) | ||
| Cho/NAA | 1 | 0.52±0.08 | 0.58±0.09 | 0.41±0.08 | |
| 2 | 0.51±0.10 | 0.57±0.08 | 0.45±0.08 | ||
| Statistics T(P) | –1.00 (0.340) | –0.73 (0.488) | 1.96 (0.072) | ||
| Right thalamus | NAA/Cr | 1 | 1.83±0.18 | 1.82±0.18 | 2.19±0.20 |
| 2 | 1.96±0.14 | 1.78±0.15 | 2.12±0.31 | ||
| Statistics T(P) | 3.38 (0.006) | –1.18 (0.256) | –0.88 (0.395) | ||
| Cho/Cr | 1 | 1.00±0.07 | 1.08±0.06 | 0.98±0.14 | |
| 2 | 1.04±0.10 | 1.04±0.07 | 1.01±0.09 | ||
| Statistics T(P) | 1.59 (0.140) | –1.83 (0.104) | 0.70 (0.497) | ||
| Cho/NAA | 1 | 0.55±0.06 | 0.60±0.07 | 0.45±0.06 | |
| 2 | 0.53±0.06 | 0.59±0.06 | 0.48±0.05 | ||
| Statistics T(P) | –1.06 (0.311) | –1.23 (0.292) | 1.84 (0.089) | ||
| Anterior cingulate cortex | NAA/Cr | 1 | 1.51±0.15 | 1.51±0.11 | 1.55±0.15 |
| 2 | 1.51±0.13 | 1.41±0.13 | 1.66±0.09 | ||
| Statistics T(P) | –0.12 (0.904) | –3.92 (0.002) | 2.83 (0.014) | ||
| Cho/Cr | 1 | 1.00±0.14 | 1.04±0.06 | 0.97±0.08 | |
| 2 | 1.05±0.13 | 1.06±0.08 | 0.95±0.08 | ||
| Statistics T(P) | 1.48 (0.168) | 0.79 (0.454) | –0.59 (0.565) | ||
| Cho/NAA | 1 | 0.67±0.12 | 0.69±0.05 | 0.62±0.09 | |
| 2 | 0.70±0.13 | 0.76±0.07 | 0.57±0.05 | ||
| Statistics T(P) | 1.32 (0.215) | 2.86 (0.021) | –2.15 (0.051) | ||
| Posterior part of paracentral gyrus | NAA/Cr | 1 | 1.62±0.11 | 1.62±0.13 | 1.73±0.08 |
| 2 | 1.67±0.14 | 1.54±0.19 | 1.71±0.15 | ||
| Statistics T(P) | 1.64 (0.130) | –2.11 (0.067) | –0.53 (0.607) | ||
| Cho/Cr | 1 | 0.76±0.06 | 0.81±0.03 | 0.76±0.06 | |
| 2 | 0.79±0.07 | 0.78±0.06 | 0.78±0.08 | ||
| Statistics T(P) | 1.14 (0.280) | –1.51 (0.171) | 0.57 (0.577) | ||
| Cho/NAA | 1 | 0.50±0.08 | 0.50±0.03 | 0.44±0.03 | |
| 2 | 0.47±0.04 | 0.51±0.08 | 0.45±0.04 | ||
| Statistics T(P) | -0.92 (0.380) | 0.43 (0.676) | 1.43 (0.176) |
Note: 1=pre-intervention scan; 2=post-intervention scan;
p<0.05.
Abbreviations: NAA, N-acetylaspartate; Cr, creatine; Cho, choline-containing compounds; T, t-test; P, p-value.
Figure 2Comparison of the level of metabolite ratios between subject groups at pre-and post-intervention conditions for (A) NAA/Cr and (B) Cho/Cr.
Notes: ▲= Significant difference at p<0.050 between pre- and post-intervention conditions. For each test, n=15 for each of the MwoA and CH patient groups, and n=14 for the HC group.
Abbreviations: NAA, N-acetylaspartate; Cr, creatine; Cho, choline-containing compounds; MwoA, migraine without aura; CH, cervicogenic headache; HC, healthy control.
Figure 3The relationship between NAA/Cr and VAS in thalamus at baseline and follow-up conditions.
Notes: Symbols represent the observational data and lines represent the linear fitting f(x) = a + bx, where x is the VAS scores and y is the level of metabolites. Solid lines represent the regressions for MowA patients (a1, b1), and dashed lines for the entire sample (a2, b2). Left top panel: a1=2.65, b1=–0.11 (n=15, r=–0.70, p=0.004); a2=2.33, b2=–0.07 (n=44, r=–0.60, p<0.001). Left bottom panel: a1=3.24, b1=–0.18 (n=15, r=–0.71, p=0.003); a2=2.32, b2=0.06 (n=44, r=–0.45, p=0.002). Right top panel: a1=2.55, b1=–0.10 (n=14, r=–0.64, p=0.014); a2=2.16, b2=-0.05 (n=44, r=–0.66, p<0.001). Right bottom panel: a1=2.44, b1=–0.07 (n=14, r=–0.66, p=0.010); a2=2.07, b2=–0.0 (n=44, r=–0.37, p=0.013).
Abbreviations: NAA, N-acetylaspartate; Cr, creatine; MwoA, migraine without aura; CH, cervicogenic headache; HC, healthy control; VAS, visual analog scale.
Effect of acupuncture treatment on the level of NAA/Cr adjusting for age, sex, brain region, and headache history for each subject group
| Group | Co-variables | B | Std. error | 95% CI | Beta | T | |
|---|---|---|---|---|---|---|---|
| Migraine without aura | Treatment (post vs. pre) | 0.16 | 0.05 | 0.06–0.26 | 0.33 | 3.28 | 0.002 |
| Age (year) | –0.02 | 0.01 | –0.04– –0.01 | –0.93 | –3.24 | 0.002 | |
| Sex (female vs. male) | –0.05 | 0.06 | –0.16–0.06 | –0.10 | –0.96 | 0.343 | |
| Location (left vs. right) | 0.11 | 0.05 | 0.01–0.21 | 0.21 | 2.13 | 0.038 | |
| Headache history (year) | 0.01 | 0.01 | –0.00–0.02 | 0.42 | 1.48 | 0.144 | |
| Cervicogenic headache | Treatment (post vs. pre) | –0.05 | 0.05 | –0.15–0.04 | –0.13 | –1.15 | 0.255 |
| Age (year) | –0.01 | 0.00 | –0.02– –0.00 | –0.47 | –3.62 | 0.001 | |
| Sex (female vs. male) | –0.13 | 0.05 | –0.23– –0.02 | –0.28 | –2.32 | 0.024 | |
| Location (left vs. right) | 0.10 | 0.05 | 0.00–0.19 | 0.23 | 2.08 | 0.042 | |
| Headache history (year) | –0.01 | 0.01 | –0.03–0.02 | –0.06 | –0.51 | 0.615 | |
| Healthy control | Treatment (post vs. pre) | –0.04 | 0.07 | –0.19–0.10 | –0.06 | –0.59 | 0.559 |
| Age (year) | –0.16 | 0.04 | –0.24– –0.09 | –0.52 | –4.37 | 0.000 | |
| Sex (female vs. male) | –0.06 | 0.09 | –0.24–0.11 | –0.08 | –0.72 | 0.478 | |
| Location (left vs. right) | 0.20 | 0.07 | 0.06–0.35 | 0.30 | 2.77 | 0.008 | |
| Headache history (year) | NA |
Note: B represents the correlation coefficient.
Abbreviation: NA, not applicable.